Rare Intestinal Cancer Responds to Combined Immune Therapy
A case report in Frontiers in Oncology describes a patient with rare intestinal hepatoid adenocarcinoma who achieved complete remission of ...
A case report in Frontiers in Oncology describes a patient with rare intestinal hepatoid adenocarcinoma who achieved complete remission of ...
A prospective phase II trial reports that orelabrutinib combined with sintilimab achieved a 60.7 percent response rate and a median ...
A case report describes fulminant sintilimab-associated myocarditis progressing to complete atrioventricular block despite a preserved ejection fraction, with suspected myositis–myasthenia ...
A case report describes a man with giant unresectable hepatocellular carcinoma whose inferior vena cava tumor thrombus regressed completely after ...
A retrospective three-center study of 156 patients shows that a new ABT score, built from the alkaline phosphatase to prealbumin ...
A 2026 case report describes a 42-year-old man whose bleeding splenic lesions were diagnosed as primary splenic angiosarcoma after splenectomy, ...
A phase II trial found that preoperative chemo-immunotherapy with sintilimab achieved major pathological responses in 59.1 percent of locally advanced ...
A case report describes advanced ovarian cancer shrinking dramatically after the PD-1 inhibitor sintilimab was added to chemotherapy, enabling complete ...
A phase II trial found that adjuvant sintilimab monotherapy after surgery met its primary efficacy endpoint with 87.5 percent one-year ...
A phase II trial found that nanoparticle polymeric micellar paclitaxel combined with carboplatin and sintilimab produced an objective response rate ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine